Mike Seganish
Distinguished Scientist, Discovery Chemistry Merck & Co
Michael has worked at MSD for 18 years in the discovery chemistry group. Over the past 6 years he has focused on building capabilities in ADCs and targeted delivery at the South San Francisco, California site. These efforts have focused on novel ADC targets, novel payloads as well as novel formats including peptide drug conjugates, the results of which have been a rapidly growing preclinical as well as late-stage clinical pipeline of novel ADCs.
Seminars
Monday 8th March 2027
Leveraging Advanced Models to Complement Preclinical Safety & Combination Risk Assessment
10:00 am
- Understanding the potential clinical toxicity of ADCs in the discovery space is critical for next-generation ADC design
- Discussing how preclinical models can help understand potential safety/clinical liabilities and test possible solutions
- How to effectively assess the risks of pre-clinical safety
